Organization
The University of Texas MD Anderson Cancer Institute
1 abstract
Abstract
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies.Org: SCRI at TriStar Centennial, The University of Texas MD Anderson Cancer Institute,